Skip to main content

Image Guided Programming

Precision in Sight

Image Guided Programming with STIMVIEW XT – see deep brain stimulation like never before.

STIMVIEW XT offers a streamlined approach to personalized DBS programming. 

See stimulation. Personalize Therapy. In each patient’s specific anatomy.

Vercise Genus deep brain stimulation system. IPGs, leads and STIMVIEW XT on tablet.

Personalize therapy

Introducing STIMVIEW XT - the latest innovation in Boston Scientific’s Image Guided Programming technology.

STIMVIEW XT is used with the Vercise Genus Deep Brain Stimulation (DBS) portfolio and is designed to be the most advanced visualization software for DBS programming by enabling clinicians to precisely see, shape, and steer DBS therapy. The software seamlessly integrates into the programming interface and uses patient-specific 3D visualization of the anatomy for clinicians to better personalize therapy.

STIMVIEW XT empowers DBS programmers to optimize and deliver directional stimulation more efficiently. In a recent study, DBS programmers were able to program patients in an average of 20 minutes1 and reduce programming time by 56%.*

A. Stimulation Field model within each patient’s specific anatomy

B. Intuitive steering controls

C. Automatic lead orientation

Hear from the experts how Image Guided Programming with STIMVIEW XT creates a more streamlined and efficient workflow

Clinicians share their experience with Image Guided Programming with STIMVIEW XT

Learn how Image Guided Programming with STIMVIEW XT is impacting the efficiency of patient programming

See the lead – informed DBS programming

Through our exclusive partnership with Brainlab, DBS programmers can use the Boston Scientific Clinician Programmer with Brainlab Elements to identify the location of the leads within the patient's specific anatomy to inform programming.  

Brainlab Elements are efficient, effective, a la carte software modules serving multiple clinical specialties.

With Brainlab Elements Lead Localization and Elements Anatomical Mapping, neurosurgeons and neurologists can see the Vercise™ Cartesia directional lead in the patient’s own segmented anatomy and correlate stimulation location to outcomes to assist in programming. 

In a recent study, DBS programmers were able to program patients in an average of 20 minutes1 and reduce programming time by 56% with Boston Scientific’s Image Guided Programming technology.*

Boston Scientific Clinician Programmer with Brainlab Elements on tablet.

A. Display of lead orientation within the anatomy

B. Identify contacts within the target

With Brainlab Elements you are able to: 

  • See the lead in each patient’s specific anatomy.
  • See the contacts within the anatomical target.
  • See the orientation of the lead.

This offers an informed starting point for DBS programming and reduces programming time.

See the lead in 3 easy steps

Use Brainlab Elements on the Boston Scientific DBS Clinician Programmer to assist during your programming session in 3 easy steps.

3 easy steps to see the lead

  1. Image fusion 
  2. Anatomical mapping 
  3. Lead localization

Precision takes shape

Easily customize therapy to match each patient’s needs with the Vercise Genus™ DBS System.


Precision delivered

The Vercise Genus DBS System features directional and standard leads powered by Cartesia 3D.**


Clinical excellence

The Vercise™ DBS Systems are supported by dozens of studies with thousands of patients worldwide showing clinical benefits.

Reference:

1. Lange F, et al. (2021). Reduced Programming Time and Strong Symptom Control Even in Chronic Course Through Imaging-Based DBS Programming. Front. Neurol. 12:785529.doi: 10.3389/fneur.2021.785529 n=10

*Compared with standard clinical based programming, p=0.039

**Note: Stimulation using multiple independent current control (MICC) with a Directional Lead is referred to as Cartesia 3D

Images provided by Brainlab

Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.

The Bluetooth® word mark and logos are registered trademarks owned by the Bluetooth SIG, Inc. and any use of such marks by Boston Scientific Neuromodulation Corporation is under license.

Brainlab Elements Image Fusion is an application for the co-registration of image data within medical procedures by using rigid and deformable registration methods. It is intended to align anatomical structures between data sets. The device itself does not have clinical indications.

The Brainlab Elements Trajectory Planning software is intended for pre-, intra- and postoperative image-based planning and review of either open or minimally invasive neurosurgical and neurological procedures. Its use is indicated for any medical condition in which the use of stereotactic surgery may be appropriate for the placement of instruments/devices and where the position of the instrument / device can be identified relative to images of the anatomy. This includes, but is not limited to, the following Cranial procedures (including frame-based stereotaxy and frame alternative-based stereotaxy):

  • Lead placement and detection (DBS procedures)

iPlan's indications for use are the viewing, presentation, and documentation of medical imaging, including different modules for image processing, image fusion, atlas assisted visualization and segmentation, intraoperative functional planning where the output can be used e.g. with stereotactic image guided surgery or other devices for further processing and visualization. Example procedures include, but are not limited to:

  • Planning and simulation of cranial surgical procedures such as tumor resection, shunt placement, minimal-invasive stereotactic interventions, biopsy, planning, and simulation of trajectories for stimulation and electrode recording.

Indication for Use: The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

  • Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.  

  • Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability.                        

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:

  • Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

Contraindications, warnings, precautions, side effects: The Deep Brain Stimulation Systems or any of its components, is contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Vercise™ DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific Deep Brain Stimulation Systems without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia™ or Vercise Genus™ or Vercise Genus Mixed System with M8 Adaptor or Vercise DBS Lead-only system (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately. Refer to the Instructions for Use provided with the Vercise DBS System or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.